A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

NCT04704154 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

175

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: Regorafenib, (Stivarga, BAY73-4506)
DRUG: Nivolumab (Opdivo)

Sponsor

Bayer

Collaborators

[object Object]